Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cerilliant
Fish and Richardson
McKinsey
Healthtrust
Johnson and Johnson
McKesson
Daiichi Sankyo
Deloitte
Covington

Generated: October 22, 2017

DrugPatentWatch Database Preview

Sarepta Theraps Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SAREPTA THERAPS INC, and when can generic versions of SAREPTA THERAPS INC drugs launch?

SAREPTA THERAPS INC has one approved drug.

There are five US patents protecting SAREPTA THERAPS INC drugs.

There are one hundred and fifty-five patent family members on SAREPTA THERAPS INC drugs in twenty-one countries.

Summary for Applicant: Sarepta Theraps Inc

International Patents:155
US Patents:5
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-002Sep 19, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-002Sep 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-001Sep 19, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-001Sep 19, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-001Sep 19, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-002Sep 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-002Sep 19, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-001Sep 19, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-001Sep 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-002Sep 19, 2016RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Sarepta Theraps Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,759,307Oligonucleotide compound and method for treating nidovirus infections► Subscribe
8,436,163Splice-region antisense composition and method► Subscribe
8,455,634Antisense oligonucleotides for inducing exon skipping and methods of use thereof► Subscribe
9,605,262Antisense oligonucleotides for inducing exon skipping and methods of use thereof► Subscribe
9,441,229Antisense oligonucleotides for inducing exon skipping and methods of use thereof► Subscribe
8,785,407Antisense antiviral agent and method for treating ssRNA viral infection► Subscribe
9,534,220Antisense antibacterial method and compound► Subscribe
9,249,416Antisense oligonucleotides for inducing exon skipping and methods of use thereof► Subscribe
7,807,816Antisense oligonucleotides for inducing exon skipping and methods of use thereof► Subscribe
7,507,196Antisense antiviral compounds and methods for treating a filovirus infection► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sarepta Theraps Inc Drugs

Country Document Number Estimated Expiration
New Zealand592446► Subscribe
World Intellectual Property Organization (WIPO)2010054267► Subscribe
Japan2016516066► Subscribe
World Intellectual Property Organization (WIPO)2006000057► Subscribe
Australia2014233456► Subscribe
European Patent Office2614827► Subscribe
European Patent Office1814596► Subscribe
European Patent Office2968991► Subscribe
World Intellectual Property Organization (WIPO)2007056466► Subscribe
Denmark1766012► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
US Army
McKesson
Chubb
AstraZeneca
Cantor Fitzgerald
Accenture
Deloitte
QuintilesIMS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot